Canopy Growth stock tumbles after announcing $200 million share sale plan
Ensysce Biosciences, Inc., a pharmaceutical company based in La Jolla, California, announced today a correction to its Annual Report filing. The company disclosed that the original Consent of Independent (LON:IOG) Registered Public Accounting Firm, dated March 10, 2025, lacked references to two of its Registration Statements on Form S-3. The corrected document, dated April 1, 2025, has been filed with the Securities and Exchange Commission (SEC) and includes the necessary references. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.42, indicating strong ability to meet short-term obligations.
The oversight pertained to Registration Statements No. 333-275456 and No. 333-276537. The Revised Consent now attached as Exhibit 23.1 to the Form 8-K, ensures compliance with SEC regulations. Ensysce emphasized that the correction does not affect any financial results or disclosures previously reported for the fiscal year ended December 31, 2024. The company’s financial position shows it holds more cash than debt on its balance sheet, though InvestingPro analysis indicates the stock is currently trading below its Fair Value.
The company, listed on The Nasdaq Stock Market LLC under the ticker ENSC, specializes in pharmaceutical preparations and operates under the jurisdiction of Delaware. The announcement of the corrected filing was made in accordance with SEC protocols to maintain transparency with investors and regulatory bodies.
This correction is a procedural update and Ensysce Biosciences has confirmed that all financial statements and disclosures remain unchanged from those reported in the original Form 10-K. The information is based on a press release statement.
In other recent news, Ensysce Biosciences, Inc. has raised approximately $1.1 million through a stock sale involving both a registered direct offering and a private placement. The company sold 315,188 shares at $3.49 each, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds are earmarked for the development of Ensysce’s TAAP™ and MPAR® programs, as well as for working capital. Additionally, Ensysce has reported positive interim data from a clinical trial of its drug candidate PF614-MPAR, which showed significant overdose protection. The trial, PF614-MPAR-102, demonstrated a lower maximum blood concentration of oxycodone in subjects taking the MPAR product compared to PF614 alone. This development follows the drug’s Breakthrough Therapy designation from the FDA and support from a $14 million award by the National Institute on Drug Abuse. The ongoing trial will continue to assess food effects and repeat dosing. These recent developments highlight Ensysce’s progress in advancing safer pain management solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.